Weekly Brief


Weekly Brief

Thursday, March 19,2020

Feature of the Week

The digital universe has grown exponentially over the last few years and is expected to reach 44 trillion gigabytes this year.  Read more
To meet the needs of regular corporate clients, the company is eyeing a larger share of what CEO Jeff Grass sees as a $65 billion catering market  Read more
The company intends to use the newly raised capital to digitize the next generation of brick-and-mortar retail and shopping centers on a global level  Read more
Kymera Therapeutics is developing targeted protein degradation to invent breakthrough protein degrader medicines for patients.  Read more

CIO Viewpoint

By Salumeh Companieh, CIO, C&W Services  
Whatever your industry, chances are you have access to important data that could fundamentally change the way you do business. The trick is figuring out how to use it optimally.  Read more
By Steven John, CIO, AmeriPride  
Transforming IT Infrastructure to Enhance Customer Service.  Read more

Featured Vendors

By George Wrenn, Founder & CEO  
Provides a SaaS solution that enables continuous improvement of an organizations cybersecurity posture and manage an effective cyber strategy  Read more
By John Butler, Co-Founder & CEO  
QuantumCyte is a biotech platform that works in the area of developing an effective cancer treatment. With a mission to make patient biopsies faster and more accurate, the company aims to gain precise results on drug therapy. The vision behind the...  Read more
By Yochi Slonim, Co-founder and CEO  
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases.  Read more

CXO Insights

By Ryan Wang, Co-Founder & General Partner, Outpost Capital  
Given the ability of these inventions to redefine the perception of reality, it goes without saying...  Read more
By Ulrich Geilinger, Venture Capitalist, HBM Partners AG  
One of the most profitable and but also very risky venture is the development of a new drug that...  Read more